<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147004</url>
  </required_header>
  <id_info>
    <org_study_id>QLK2-CT-2000-00589</org_study_id>
    <secondary_id>EC- QLK2-CT-2000-00589</secondary_id>
    <nct_id>NCT00147004</nct_id>
  </id_info>
  <brief_title>Corticosteroid Therapy of Septic Shock - Corticus</brief_title>
  <acronym>Corticus</acronym>
  <official_title>Corticosteroid Therapy of Septic Shock - Corticus. A Multi-National, Prospective, Double-Blind, Randomized, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Society of Intensive Care Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Sepsis Forum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Gorham Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether steroids decrease 28-day mortality in
      patients with septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of steroids in septic shock remains controversial. The purpose of this study is to
      determine whether hydrocortisone decreases 28-day mortality in patients with septic shock.
      The primary end point will be 28-day mortality in all the non-responders to ACTH (&lt; or = 9
      mcg/dl or 250 nmol/L post ACTH). Secondary endpoints will be 28 day all cause mortality in
      the total group and in responders, ICU and hospital mortality, one year mortality, organ
      system failure reversal especially shock, and duration of ICU and total hospitalisation.

      In a double-blinded fashion (randomized on a 1:1 basis), patients receive 50 mg intravenously
      every 6 hours for 5 days. After 5 days, treatment will be tapered with 50 mg given
      intravenously every 12 hours for days 6-8, then 50 mg every 24 hours for days 9-11, and then
      stopped.

      All concomitant treatments, including antibiotics, fluids, vasopressors and ancillary
      therapies will be given at the discretion of the primary care physician. Evidence-based
      guidelines for the management of severe sepsis and septic shock by the International Sepsis
      Forum (Intensive Care Med 2001;27:S124-S134) are encouraged to be followed.

      All serious adverse events (SAE) which occur between days 0 and 28, which are unexpected
      and/or considered possibly or probably related to the study medication, must be documented
      and reported within 24 hours to the Safety and Efficacy Monitoring Committee. Non-serious
      adverse events will be listed on the case report form if they are unexpected and believed to
      be related to the study drug during days 0 to 14.

      Specific adverse events which will be monitored closely because of their relationship to
      corticosteroids and shock are:

        1. Use of corticosteroids, i.e. gastrointestinal bleeding and superinfection;
           hyperglycemia, hypernatremia, muscular weakness, etc.

        2. Shock and use of vasopressors, i.e. stroke, acute myocardial infarction and peripheral
           ischemia.

      In addition, substudies will include harmonization of cortisol by comparing cortisol levels
      measured in local laboratories and a central laboratory, immune and neuro-endocrine
      interactions, neuromuscular weakness and cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 day mortality in all the non-responders to ACTH (&lt; or = 9 mcg/dl or 250 nmol/L post ACTH)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 day all cause mortality in the total group.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28 day all cause mortality in responders.</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One year mortality in nonresponders, total and responders.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital mortality.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Organ system failure reversal, especially shock.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU and total hospitalisation.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hydrocortisone sodium succinate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrocortisone sodium succinate</intervention_name>
    <description>50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical evidence of infection within the previous 72 hours (may be present longer
             than 72 hours) (a, b, c, or d - only 1 required)

               1. Presence of polymorphonuclear cells in a normally sterile body fluid (excluding
                  blood);

               2. Culture or Gram stain of blood, sputum, urine or normally sterile body fluid
                  positive for a pathogenic micro-organism;

               3. Focus of infection identified by visual inspection (e.g. ruptured bowel with the
                  presence of free air or bowel contents in the abdomen found at the time of
                  surgery, wound with purulent drainage);

               4. Other clinical evidence of infection - treated community acquired pneumonia,
                  purpura fulminans, necrotising fascitis, etc.

          2. Evidence of a systemic response to infection as defined by the presence of two or more
             of the following signs within the previous 24 hours. These signs may be present longer
             than 72 hours.

               1. Fever (temperature &gt;38.3°C) or hypothermia (rectal temperature &lt; 35.6°C);

               2. Tachycardia (heart rate of &gt;90 beat/min);

               3. Tachypnea (respiratory rate &gt; 20 breaths/min, PaC02&lt;32 mmHg) or patient requires
                  invasive mechanical ventilation;

               4. Alteration of the WBC count &gt;12,000 cells/mm3, &lt;4,000 cells/mm3 or &gt;10% immature
                  neutrophils (bands).

          3. Evidence of shock defined by (A + B- both required within the previous 72 hours (may
             NOT be present longer than 72 hours).

        A. A systolic blood pressure &lt; 90 mmHg or a decrease in SBP of more than 50 mmHg from
        baseline in previous hypertensive patients (for at least one hour) despite adequate fluid
        replacement OR need for vasopressors for at least one hour (infusion of dopamine ≥ 5
        mcg/kg/min or any dose of adrenaline, noradrenaline, phenylephrine or vasopressin) to
        maintain a SBP ≥ 90 mmHg;

        B. Hypoperfusion or organ dysfunction which is not the result of underlying diseases or
        drugs, but is attributable to sepsis, including one of the following:

          1. Sustained oliguria (urine output &lt; 0.5 ml/kg/hr for a minimum of 1 hour)

          2. Metabolic acidosis [pH of &lt; 7.3, or a base deficit of &gt; or = 5.0 mmol/L, or an
             increased lactic acid concentration (&gt; 2 mmol/L)].

          3. Arterial hypoxemia (Pa02/FI02&lt;280 in the absence of pneumonia)(Pa02/FI02&lt;200 in the
             presence of pneumonia).

          4. Thrombocytopenia - platelet count ≤ 100,000 cells/mm3.

          5. Acute altered mental status (Glasgow Coma Scale &lt; 14 or acute change from baseline).

        4. Informed Consent

        5. Cortisol level at baseline and 60 minutes after 0.25 mg cosyntropin

        Exclusion Criteria:

          1. Pregnancy

          2. Age less than 18.

          3. Underlying disease with a prognosis for survival of less than 3 months.

          4. Cardiopulmonary resuscitation within 72 hours before study.

          5. Drug-induced immunosuppression, including chemotherapy or radiation therapy within 4
             weeks before the study.

          6. Administration of chronic corticosteroids in the last 6 months or acute steroid
             therapy (any dose) within 4 weeks (including inhaled steroids). Topical steroids are
             not exclusions.

          7. HIV positivity.

          8. Presence of an advanced directive to withhold or withdraw life sustaining treatment
             (i.e. DNR).

          9. Advanced cancer with a life expectancy less than 3 months.

         10. Acute myocardial infarction or pulmonary embolus.

         11. Another experimental drug study within the last 30 days.

         12. Moribund patients likely to die within 24 hours.

         13. Patients in the ICU for more than 2 months at the time of the start of septic shock.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles L Sprung, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hadasah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Djillali Annane, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hopital Raymond Poincare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Josef Briegel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ludwig-Maximilian-Universitaet Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Keh, MD</last_name>
    <role>Study Director</role>
    <affiliation>Charite Campus Virchow-Klinikum</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rui Moreno, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de St. António dos Capuchos</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Didier Pittet, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mervyn Singer, MD</last_name>
    <role>Study Director</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH-BHS Linz</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Ges. mbH</name>
      <address>
        <city>Linz</city>
        <zip>A-4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik fuer Innere Medizin II</name>
      <address>
        <city>Wien</city>
        <zip>A 1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital St. Joseph</name>
      <address>
        <city>Arlon</city>
        <zip>B-6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Erasme</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St. Luc, UCL</name>
      <address>
        <city>Brussels</city>
        <zip>B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>B-6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Raymond Poincare</name>
      <address>
        <city>Paris</city>
        <state>Garches</state>
        <zip>F-92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <state>Oarus</state>
        <zip>F-75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez</name>
      <address>
        <city>Lille</city>
        <zip>F-59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30029 cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>F-75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes-Klinikum im Friedrichshain</name>
      <address>
        <city>Berlin</city>
        <zip>D - 10249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes-Klinikum Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>D - 13585</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Waldkrankenhaus Spandau</name>
      <address>
        <city>Berlin</city>
        <zip>D - 13589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>D-12101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes-Klinikum Neukoelln</name>
      <address>
        <city>Berlin</city>
        <zip>D-12313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Campus Charité Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow -Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité- Campus Virchow- Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Anaesthesia and Operative Intensive Care</name>
      <address>
        <city>Darmstadt</city>
        <zip>D-64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D- 01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Hennigsdort</name>
      <address>
        <city>Hennigsdorf</city>
        <zip>D-16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Schiller Universitaet</name>
      <address>
        <city>Jena</city>
        <zip>D - 07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kemptern-Oberallegaeu</name>
      <address>
        <city>Kempten</city>
        <zip>D-87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>D-84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mannheim, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <zip>D- 68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Muenchen-Harlaching</name>
      <address>
        <city>Muenchen</city>
        <zip>D- 81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilian-Universitaet Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>D-81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern, LMU Munich</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univesitaet Erlangen-Namberg</name>
      <address>
        <city>Nurenberg</city>
        <zip>D-90471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergman</name>
      <address>
        <city>Potsdam</city>
        <zip>D-14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haemek Hospital</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organisation</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beilinson Medical Centre</name>
      <address>
        <city>Petach Tikva</city>
        <zip>491000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ichilov Hospital</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico di Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro di Rianimazione Ospedale S.Eugenio</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renier de Graaf Hospital</name>
      <address>
        <city>Delft</city>
        <zip>2600 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Centre</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de St. Antonio do Capuchos</name>
      <address>
        <city>Lisboa</city>
        <zip>1150</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCIP, Hospital de Desterro</name>
      <address>
        <city>Lisbon</city>
        <zip>1150</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Egas Moniz</name>
      <address>
        <city>Lisbon</city>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southend Hospital</name>
      <address>
        <city>Essex</city>
        <zip>SSO ORY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Lancaster Infirmary</name>
      <address>
        <city>Lancaster</city>
        <zip>LA1 4RP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The General Infirmary at Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bloomsbury Institute of Intensive Care Medicine</name>
      <address>
        <city>London</city>
        <zip>W1T 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Manchester, Hope Hospital</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003 May 22;348(21):2157-9.</citation>
    <PMID>12761380</PMID>
  </reference>
  <results_reference>
    <citation>Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J; CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008 Jan 10;358(2):111-24. doi: 10.1056/NEJMoa071366.</citation>
    <PMID>18184957</PMID>
  </results_reference>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Charles Sprung</name_title>
    <organization>Hadassah Medical Organization</organization>
  </responsible_party>
  <keyword>Septic shock</keyword>
  <keyword>Steroids</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Mortality</keyword>
  <keyword>Reversal of shock</keyword>
  <keyword>Adrenal insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

